US FDA Eyes Ways To Improve Conduct, Mitigate Bias In Open-Label Cancer Studies
Executive Summary
At advisory committee review of confirmatory trial results for Amgen’s Lumakras, Oncology Center of Excellence’s Richard Pazdur cites need for a broader conversation within the clinical trial community, including educating patients and investigators about the importance of staying on study even when randomized to a comparator arm.